Ka Yi Lau

Over 8 years’ work experience in the field of clinical research, including 6 years of clinical trial monitoring experience. Responsible for studies in different therapeutic areas from Phase I to Phase III, including oncology, hematology and infectious diseases. Excellent site management skills and familiar with studies process from startup, routine monitoring to site closure, and delivering high-quality results.

• Monitoring Experience:
  Experienced in all stages of clinical trial monitoring, including feasibility, site initiation (SIV), monitoring visits (IMV), and close-out visits (COV). Work has been carried out both on-site and remotely.
• Site Management:
  Currently managing 10 sites
• Protocol Management:
  Overseeing 7 protocols at the same time
• Monitoring Frequency: 6 on-site monitoring days per month, with all reports submitted on time
  Remote: About 1 remote visit per month for each study
• Submission Experience: Completed Ethics Committee (EC) submissions (initial, amendments, annual reports, and closures) with high approval rates and few queries; Supported Regulatory Authority (RA) submissions, following local requirements
• Therapeutic Areas:
  Experience in Hematology, Immunology, Oncology, Infectious Diseases, and Rheumatology
• Clinical Trial Phases:
  Experience in Phase I, Phase II and III trials, supporting database lock and study completion on time

XXXX

• Experimental Cell Research, Ling-Ming Tseng, Ka-Yi Lau, Ji-Lin Chen, Pei-Yi Chu, Tzu-Ting Huang, Chia-Han Lee, Wan-Lun Wang, Yuan-Ya Chang, Chun-Teng Huang, Chi-Cheng Huang, Ta-Chung Chao, Yi-Fang Tsai, Jiun-I Lai, Ming-Shen Dai, Chun-Yu Liu, Experimental Cell Research Volume 429, Issue 1, 1 August 2023, 113652, 2023
• EBioMedicine, TT Huang, LM Tseng, JL Chen, PY Chu, CH Lee, CT Huang, WL Wang, KY Lau, MF Tseng, YY Chang, TY Chiang, YF Ueng, HC Lee, MS Dai, CY Liu., Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression., 2020
• PLoS ONE, CY Liu, KY Lau, CC Hsu, JL Chen, CH Lee, TT Huang, YT Chen, CT Huang, PH Lin, LM Tseng., Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells, 2017